Identifying the Optimal Market Entry Point for a Game-Changing Cancer Therapy

Our Client & Their Goals

Our Client, an established medical device company, was seeking a strategy to commercialise their game-changing cancer therapy. Before making this substantial investment, they asked us to help them design a strategy to commercialise their new therapy quickly and identify the ideal market entry point.

To commercialise this new cancer therapy, our Client required a comprehensive benchmark evaluating their solution against the relevant competitors. They also needed guidance on positioning their therapy within the treatment value chain. Additionally, they needed guidance on identifying potential product development and clinical trial partners, obtaining CE certification for their treatment’s devices, and confirming their target geographic markets. Our client trusted that CamIn’s expert consulting model and world-class expert teams would help them quickly identify the most effective strategy for successfully commercialising their new therapy.

CamIn's Solution

CamIn’s leaders assembled an expert consulting team of six world-class technology and industry experts to develop the commercialisation strategy of our client’s cancer therapy.

First, our project team completed technology and industry landscapes and forecasts, evaluating the markets where our Client’s new therapy was intended to compete. Our team then conducted a comprehensive technology portfolio benchmarking study to confirm the new therapy’s value proposition for specific cancers and in targeted geographies. The team also identified the market opportunity for our Client’s alternative cancer therapy across the globe against conventional and alternative competitive treatments.

Our team engaged with potential end-users to identify their key requirements, assess challenges related to the CE certification process, and identify opportunities to promote the adoption of our Client’s therapy. We also highlighted product development steps that would support the value chain positioning and commercialisation efforts for our Client’s therapy.

We then conducted an in-depth review of clinical trials and cancer statistics. Determining the frequency of the occurrence of different types of cancers helped us confirm the market demand for our Client’s therapy. Our analysis of recent clinical trials helped us develop a list of hospitals that would be suitable partners for subsequent clinical trials involving our Client’s new therapy.

Finally, we confirmed the optimal go-to-market strategy for specific cancers and geographical markets, and ensured our client’s technology was both commercially and technologically competitive in these markets.

Six months after working with CamIn, our Client started their multi-million-dollar commercialisation effort and the associated clinical trials, and commenced work on the product development steps we recommended.

The Impact

Our analysis identified the most effective commercialisation route for our Client’s new therapy, and our guidance ensured they entered markets where it would be both commercially and technologically competitive.

By working with CamIn and the world-class expert consulting team, our Client accelerated their go-to-market strategy. They prioritised clinical trials for three types of cancer in four geographical regions which our product development and clinical trial partner analyses had identified. The commercialisation path we recommended allowed them to respond to a market push for new therapies, avoid major competitors, and target many types of cancer that their therapy could address.

This specific path could only be found quickly with our consulting model and our expert team, and our Client was impressed by our consideration of both technological and commercial factors. Six months after working with CamIn, our Client started their multi-million-dollar commercialisation effort and the associated clinical trials, and commenced work on the product development steps we recommended.